RxDoctor Payments Data

Kenneth Mills, MD

Internal Medicine · San Francisco, CANPI 1023016292

Payments from drug & device makers

$3,779in general payments, 2019–2025

Across 171 payments — averaging $22.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Gilead$555
  • Merck$547
  • AbbVie$192
  • Theratechnologies Inc.$165
  • Johnson & Johnson$118
  • plus $511 from 13 others

What the payments were for

  • Food & beverage$3,762100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,779 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$57,308
Medicare patients
80
Services billed
625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala47$235,356
TivicayDolutegravir Sodium62$150,855
TriumeqAbacavir/Dolutegravir/Lamivudi33$127,622
DescovyEmtricitabine/Tenofov Alafenam51$124,550
OdefseyEmtricitab/Rilpiviri/Tenof Ala21$77,487
MytesiCrofelemer20$45,697
EliquisApixaban46$31,043
FarxigaDapagliflozin Propanediol25$21,155
OzempicSemaglutide19$19,655
XareltoRivaroxaban15$19,396
Etravirine16$16,299
Maraviroc13$16,062
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df11$15,021
Abacavir-LamivudineAbacavir Sulfate/Lamivudine11$12,682
TrulicityDulaglutide11$10,771

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$555$359,90698 claims
Viiv Healthcare CompanyTivicay, Triumeq$1,692$278,47795 claims
Napo Pharmaceuticals IncMytesi$22$45,69720 claims
PfizerEliquis$88$31,04346 claims
AstraZenecaFarxiga$92$21,15525 claims
Novo NordiskOzempic$13$19,65519 claims
Johnson & JohnsonXarelto$118$19,39615 claims
MerckJanuvia$547$6,34311 claims
Boehringer IngelheimSpiriva Respimat$91$5,70711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →